

Surveillance template protocol for *pfhrp2/pfhrp3* gene deletions



Surveillance template protocol for *pfhrp2/pfhrp3* gene deletions



Surveillance template protocol for pfhrp2/pfhrp3 gene deletions

ISBN 978-92-4-000203-6 (electronic version)

ISBN 978-92-4-000204-3 (print version)

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Surveillance template protocol for pfhrp2/pfhrp3 gene deletions. Geneva: World Health Organization; 2020. [Licence: CC BY-NC-SA 3.0 IGO](#).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Disclaimers

1. This recommended template protocol has been developed by WHO to guide surveillance for *pfhrp2/3* gene deletions in malaria endemic countries; however, WHO cannot accept any responsibility or liability for the conduct of studies by third parties that follow the protocol.
2. Studies conducted by third parties pursuant to the protocol cannot be considered “WHO studies”. Appropriate approval(s) at local and/or national level should be obtained prior to the start of any such study.

Title	
Surveillance site(s)	<p>Site 1: Name, city, district and province</p> <p>Site 2: Name, city, district and province</p> <p>Site 3: Name, city, district and province</p> <p><i>(Add more sites as needed or include just counties and add annex with health facilities list)</i></p>
Protocol submission date	dd/mmm/yyyy
Protocol number	Unique protocol number/version number
Principal investigator	<p>Name:</p> <p>Degree:</p> <p>Institution:</p> <p>Address: street, city, postal code, country</p> <p>Tel:</p> <p>Email:</p>
Co-investigators (insert additional name(s) if needed)	<p>Name:</p> <p>Degree:</p> <p>Institution:</p> <p>Address: street, city, postal code, country</p> <p>Tel:</p> <p>Email:</p>
Participating institutions (insert additional institution(s) if needed)	<p>Name:</p> <p>Complete postal address: street, city, postal code, country</p> <p>Tel:</p> <p>Email:</p>
Planned survey dates	From mmm/yyyy to mmm/yyyy
Sponsor	<p>Complete postal address: street, city, postal code, country</p> <p>Tel:</p> <p>Email:</p>

Project summary

Surveillance objectives	<p>This surveillance activity is intended to determine whether the local prevalence of mutations in the <i>P. falciparum</i> <i>hrp2/3</i> genes causing false negative RDTs has reached a threshold that might require a local or national change in diagnostic strategy. The specific objectives are to:</p> <ol style="list-style-type: none">1. Measure the prevalence of suspected false-negative HRP2 RDT results among symptomatic patients attending public health facilities with <i>P. falciparum</i> infection detected by microscopy or a pf-pLDH RDT;2. Detect the parasite density and frequency of <i>pfhrp2/3</i> gene deletions in that cohort;3. Determine the predictive value of false-negative HRP2 RDT results for <i>pfhrp2/3</i> gene deletions in different settings;4. Identify provinces in which the prevalence of <i>pfhrp2/3</i> gene deletions causing false negative <i>P. falciparum</i> RDTs is at or above 5%, warranting a change in RDTs.
Surveillance site	Pre-selected public health facilities representing the spectrum of transmission and geographical diversity across the country
Target population	Individuals seeking care for febrile illness at health facilities
Survey type	Cross-sectional, multi-site
Primary output measures	<ol style="list-style-type: none">1. Prevalence of suspected false-negative HRP2 RDT results among symptomatic patients with <i>P. falciparum</i> malaria.2. Prevalence of <i>pfhrp2/3</i> gene deletions among symptomatic falciparum patients with a false-negative HRP2 RDT result3. Prevalence of <i>pfhrp2/3</i> gene deletions causing false negative HRP2 RDTs amongst all symptomatic <i>P. falciparum</i> confirmed cases.
Secondary output measures (optional)	<ol style="list-style-type: none">1. Parasite density, as measured by quantitative PCR and/or microscopy, in patients with suspected false-negative HRP2 RDT results.
Sample size	A sample size of 370 confirmed <i>P. falciparum</i> cases per sampling domain (37 per health facility) is recommended to quantify whether or not the prevalence of <i>pfhrp2</i> deletion is above 5%. Once the sample of 370 <i>P. falciparum</i> cases have been enrolled then molecular confirmation of <i>pfhrp2</i> deletions amongst suspected false negative <i>P. falciparum</i> cases should ensue.
Sampling method	In at least 10 pre-selected health facilities per sampling domain eg. province at risk, a cross-sectional survey will measure the suspected and confirmed prevalence of <i>pfhrp2/3</i> gene deletions causing false-negative HRP2 RDT results. 37 <i>P. falciparum</i> confirmed cases should be included in each health facility.

Data collection

1. Identify provinces to be included in the study.
2. Select at least 10 health facilities per province for testing (facility sample size may vary depending on logistical and budgetary constraints). Any facility where RDTs are being used is eligible; however, microscopy services are not a requirement.
3. Test all individuals presenting with suspected malaria using both a WHO-recommended HRP2 RDT and a non-HRP2 method (e.g., pf-pLDH RDT (separate single or multiple test line RDT) or quality – assured microscopy in the health facility and collect minimum two dried blood spots (DBS).
4. Record demographic and clinical history details and all test results
5. Administer antimalarial therapy based on results from (either) RDT and/or microscopy and according to national guidelines.
6. Send minimum of two DBS from all Pf patients with negative HRP2 RDT and positive pf-pLDH RDT or microscopy for molecular +/– serological analysis.¹
7. Surveillance activity can stop once 370 individuals with confirmed *P. falciparum* malaria (ideally ~37/site across the 10 sites in the province) have been recorded as having *P. falciparum* in step 4.
8. Supplemental data collection options are described in Appendix 1.
9. Discard all RDTs, microscopy slides and DBS after survey results finalized and reported

Statistical and analytic plan

The prevalence of suspected false-negative HRP2 RDT results and *pfhrp2/3* gene deletions will be established at the sampling domain (e.g. provincial level), with 95% confidence intervals (CI) estimated for all point estimates. If desired, point estimates and 95% CIs can be weighted according to relative facility size or patient flows. Differences between point estimates across sociodemographic characteristics and transmission levels, or other collected variables can be determined using χ^2 and/or logistic regressions, as desired.

¹ Use of the DBS for any purpose other than surveillance for *pfhrp2/3* deletions and/or long-term storage of the DBS would require patient consent/assent and protocol review by an ethical review board

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24788

